409 related articles for article (PubMed ID: 23236020)
1. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
2. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
[TBL] [Abstract][Full Text] [Related]
3. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
Müller C; Bunka M; Reber J; Fischer C; Zhernosekov K; Türler A; Schibli R
J Nucl Med; 2013 Dec; 54(12):2168-74. PubMed ID: 24198390
[TBL] [Abstract][Full Text] [Related]
4. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
6. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
[TBL] [Abstract][Full Text] [Related]
7. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
9. Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
Fischer CR; Groehn V; Reber J; Schibli R; Ametamey SM; Müller C
Mol Imaging Biol; 2013 Dec; 15(6):649-54. PubMed ID: 23760583
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.
Müller C; Mindt TL; de Jong M; Schibli R
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):938-46. PubMed ID: 19183997
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.
Müller C; Vlahov IR; Santhapuram HK; Leamon CP; Schibli R
Nucl Med Biol; 2011 Jul; 38(5):715-23. PubMed ID: 21718947
[TBL] [Abstract][Full Text] [Related]
12. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
14. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
15. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
16. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Deberle LM; Benešová M; Becker AE; Ratz M; Guzik P; Schibli R; Müller C
Bioconjug Chem; 2021 Aug; 32(8):1617-1628. PubMed ID: 34251183
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
18. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
19. Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice.
Müller C; Bunka M; Haller S; Köster U; Groehn V; Bernhardt P; van der Meulen N; Türler A; Schibli R
J Nucl Med; 2014 Oct; 55(10):1658-64. PubMed ID: 25034091
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
